Hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2−) breast cancer is the most common subtype, characterized by heterogeneous neoadjuvant chemotherapy (NAC) responses and low pCR rates. This evidence concerns the gene NR4A1 and breast cancer.